Optimal use of lipid-altering therapy: Guidelines versus evidence

Daniel E. Hilleman

doi:10.2217/clp.13.18

Optimal use of lipid-altering therapy: Guidelines versus evidence

Department of Pharmacy Practice

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	269-272
Number of pages	4
Journal	Clinical Lipidology
Volume	8
Issue number	3
DOIs	https://doi.org/10.2217/clp.13.18
State	Published - Jun 1 2013

All Science Journal Classification (ASJC) codes

Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.2217/clp.13.18

Cite this

@article{048e7e84e3fe4b958cb378c20bd19edf,

title = "Optimal use of lipid-altering therapy: Guidelines versus evidence",

author = "Hilleman, {Daniel E.}",

year = "2013",

month = jun,

day = "1",

doi = "10.2217/clp.13.18",

language = "English (US)",

volume = "8",

pages = "269--272",

journal = "Clinical Lipidology",

issn = "1758-4299",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Optimal use of lipid-altering therapy

T2 - Guidelines versus evidence

AU - Hilleman, Daniel E.

PY - 2013/6/1

Y1 - 2013/6/1

UR - http://www.scopus.com/inward/record.url?scp=84878676511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878676511&partnerID=8YFLogxK

U2 - 10.2217/clp.13.18

DO - 10.2217/clp.13.18

M3 - Review article

AN - SCOPUS:84878676511

SN - 1758-4299

VL - 8

SP - 269

EP - 272

JO - Clinical Lipidology

JF - Clinical Lipidology

IS - 3

ER -

Optimal use of lipid-altering therapy: Guidelines versus evidence

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this